Donnai–Barrow syndrome

From WikiMD's WELLNESSPEDIA

(Redirected from Donnai-Barrow syndrome)

Autosomal recessive - en

Donnai–Barrow syndrome (DBS) is a rare genetic disorder characterized by a range of congenital anomalies and developmental delays. It is also known as faciooculoacousticorenal syndrome (FOAR). The syndrome is named after the researchers who first described it, Margaret Donnai and Michael Barrow.

Clinical Features[edit]

Individuals with Donnai–Barrow syndrome typically present with a variety of clinical features, including:

Genetics[edit]

Donnai–Barrow syndrome is caused by mutations in the LRP2 gene, which encodes the low-density lipoprotein receptor-related protein 2. This gene plays a crucial role in the development of various tissues and organs. The syndrome is inherited in an autosomal recessive manner, meaning that an individual must inherit two copies of the mutated gene, one from each parent, to be affected.

Diagnosis[edit]

The diagnosis of Donnai–Barrow syndrome is based on clinical evaluation, family history, and genetic testing. Molecular genetic testing can confirm the presence of mutations in the LRP2 gene.

Management[edit]

There is no cure for Donnai–Barrow syndrome, and treatment is primarily supportive and symptomatic. Management may include:

  • Hearing aids or cochlear implants for hearing loss.
  • Regular ophthalmologic evaluations and interventions for ocular anomalies.
  • Monitoring and management of renal function.
  • Early intervention programs and special education services to address developmental delays.

Epidemiology[edit]

Donnai–Barrow syndrome is extremely rare, with only a few dozen cases reported in the medical literature. The exact prevalence is unknown.

See Also[edit]

References[edit]


External Links[edit]

-


Medical condition






















Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.